The company plans to raise funds comprising fresh issues aggregating up to Rs 200 crore and an offer for sale of up to 56,252,644 shares.
The company proposes to utilize the net proceeds from the fresh issue towards funding the working capital requirements of material subsidiary Medybiz Pharma, repayment of loans, purchase of medical equipment, marketing and brand building and inorganic growth initiatives and general corporate purposes.
The offer for sale comprises equity shares up to 12,070,214 equity shares by Growth III Holdings (Mauritius) Limited; up to 8,504,709 equity shares by Accel India III (Mauritius) Limited, up to 4,278,680 equity shares by Ventureast Life Fund III LLC Limited; up to 4,445,735 equity shares by MEMG CDC Ventures; up to 4,256,924 equity shares by Qualcomm Asia Pacific Pte Ltd, up to 4,229,951 equity shares by Accel India V (Mauritius) Limited and up to 3,984,752 equity shares by Sabre Partners Trust.
Capital Markets Limited, and are the Book Running Lead Managers.